Structure Therapeutics (GPCR) Other Non-Current Assets (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Other Non-Current Assets of $5.6 million for Q1 2026, down 8.87% year-over-year from $6.1 million in Q1 2025, and up 674.76% quarter-over-quarter from $717000.0 in Q4 2025.
Structure Therapeutics (GPCR) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Structure Therapeutics' Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $5.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 8.87% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (down 8.87% YoY), while the FY2025 annual figure was $717000.0, down 85.96% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $5.6 million, up from $717000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $6.6 million in Q3 2025, with the low at $38000.0 in Q2 2023.
- The 5-year median for Other Non-Current Assets is $1.8 million (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets tumbled 98.7% in 2023, then surged 12870.21% in 2025.
- Structure Therapeutics' Other Non-Current Assets stood at $3.5 million in 2022, then sank by 98.7% to $45000.0 in 2023, then soared by 11246.67% to $5.1 million in 2024, then plunged by 85.96% to $717000.0 in 2025, then surged by 674.76% to $5.6 million in 2026.
- Business Quant data shows GPCR's Other Non-Current Assets at $5.6 million in Q1 2026, $717000.0 in Q4 2025, and $6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 41.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.00 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 717,000.00 |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | 6.20 Mn |
| Mar 31, 2025 | 6.10 Mn |
| Dec 31, 2024 | 5.11 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 47,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Sep 30, 2023 | 350,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Dec 31, 2022 | 3.46 Mn |